Mammogram-level AUC
0.894 AUC
- EndpointStandalone discrimination in paired DBT compatibility evaluation
- Population1,475 patients / 2,950 paired Hologic Dimensions and Envision DBT studies
- Tested versionMammoScreen 4
FDA-cleared profile
Therapixel · Mammography/DBT · FDA-cleared (510(k))
Authorized purpose: Identifies calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; it is not a standalone diagnostic device.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: Identifies calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; it is not a standalone diagnostic device.
Evidence takeaway. Evidence from the reviewed source record: Standalone comparison used 1,475 patients and 2,950 paired DBT studies; the regulatory summary reports AUC and localization endpoints for this specific compatibility evaluation.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Packet wording: "MammoScreen® 4 is a concurrent reading and reporting aid for physicians interpreting mammograms." … "Output of the device includes graphical marks of findings as soft-tissue lesions or calcifications on mammograms along with their level of suspicion scores. The lesion type is characterized as mass/asymmetry, distortion, or calcifications for each detected finding.". Read from the exact FDA decision document on 2026-11-14.
Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
No sensitivity value with complete endpoint context was abstracted.
No specificity value with complete endpoint context was abstracted.
0.894 AUC
K243679
Reference labels include biopsy-positive and benign/negative follow-up categories as described in the summary.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Price not public here; enter your quote
Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Compatible FFDM or DBT screening exams; the cleared modification adds Hologic Envision support.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-05 · MammoScreen 4: K243679 clearance and 510(k) summary
Source context, not route validation: Current family documentation describes a site gateway, DICOM output, and optional HL7/FHIR reporting integration.
Scope: Product family. Not an exact-version interface guarantee.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-06 · MammoScreen integration
Source context, not route validation: Current family documentation describes cloud computation through a site gateway and an on-premises option on request.
Scope: Product family.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-06 · MammoScreen integration
Source context, not route validation: Finding marks and finding-, breast- and case-level scores; dedicated user interface/viewer, DICOM Secondary Capture and DICOM Structured Report outputs.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-05 · MammoScreen 4: K243679 clearance and 510(k) summary
Unresolved route: Finding marks and finding-, breast- and case-level scores; dedicated user interface/viewer, DICOM Secondary Capture and DICOM Structured Report outputs.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-05 · MammoScreen 4: K243679 clearance and 510(k) summary
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Not an exact-version interface guarantee.
Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Gateway-based processing with DICOM output and optional reporting-system integration.
product family · checked 2026-09-06Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Documented product family
These links identify a sourced product-family relationship. They do not transfer evidence, metrics, clearance scope, compatibility, pricing, or availability between submissions.
A partial mapping of MammoScreen 4 and 5 reading-aid records. Density products and other releases are not included in this mapping.
Therapixel identifies MammoScreen as its screening-mammography reading software. The manufacturer-prepared K260714 summary explicitly identifies K243679 as MammoScreen 4 and describes both as software versions of MammoScreen. This does not transfer tested input scenarios, evidence, licenses or availability between records.
Latest mapped does not mean latest sold or installed. Choose an exact FDA record before comparing.
MammoScreen 4 reviewed in K243679
FDA decision: 2025-07-03 · record reviewed 2026-11-05MammoScreen 5 reviewed in K260714
Latest mapped FDA decisionFDA decision: 2026-06-26 · record reviewed 2026-11-05Research record
This audit distinguishes completed source review from fields that have not yet been researched.
Stored PMID 32159424 is an online breast-cancer risk decision-aid study, not MammoScreen evidence; excluded by metadata. No trial records stored. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor technical page, vendor product page, literature index, trial registry, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public price was located in reviewed vendor material.
Bounded web search on 2026-10-26 (query: "Therapixel MammoScreen reimbursement CPT coverage"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Therapixel's adoption page describes general US screening mammography policy; it states no coding or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
12 sources - 3 history items
Scope: regulatoryIdentity, purpose, modality, anatomy
Scope: regulatoryIdentity, modalityContext
Scope: intendedUsers, careSetting, output, evidenceSummary, anatomy, evidenceStudies
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: identity, clinical, implementation, evidence, product_family
Scope: product_family_implementation
Scope: product_family_training
Scope: identity, clinical, implementation, evidence
Scope: security
Scope: product_family
Regulatory record
510(k)
Research record
human reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Therapixel
Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
DeepHealth, Inc.
Authorized purpose: Concurrent detection and characterization support for screening DBT mammography
Neurocareai, Inc. (Dba Savelife.Ai)
Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
Lunit, Inc.
Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history